Literature DB >> 16309366

SELDI-TOF-MS proteomics of breast cancer.

Charlotte H Clarke1, Julie A Buckley, Eric T Fung.   

Abstract

The detection, diagnosis, and management of breast cancer rely on an integrated approach using clinical history, physical examination, imaging, and histopathology. The discovery and validation of novel biomarkers will aid the physician in more effectively achieving this integration. This review discusses efforts in surface-enhanced laser desorption/ionization (SELDI)-based proteomics to address various clinical questions surrounding breast cancer, including diagnosis, monitoring, and stratification for treatment. Emphasis is placed on examining how study design and execution influence the discovery and validation process, which is critical to the proper development of potential clinical tests.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16309366     DOI: 10.1515/CCLM.2005.225

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  19 in total

Review 1.  Proteomic technology for biomarker profiling in cancer: an update.

Authors:  Moulay A Alaoui-Jamali; Ying-jie Xu
Journal:  J Zhejiang Univ Sci B       Date:  2006-06       Impact factor: 3.066

2.  Insights into molecular medicine: development of new diagnostic and prognostic parameters.

Authors:  Gernot P Tilz; Marco Wiltgen; Ulrike Demel; Christian Faschinger; Hannes Schmidinger; Albin Hermetter
Journal:  Wien Med Wochenschr       Date:  2007

Review 3.  Challenges for biomarker discovery in body fluids using SELDI-TOF-MS.

Authors:  Muriel De Bock; Dominique de Seny; Marie-Alice Meuwis; Jean-Paul Chapelle; Edouard Louis; Michel Malaise; Marie-Paule Merville; Marianne Fillet
Journal:  J Biomed Biotechnol       Date:  2009-12-06

4.  Screening and identification of serum proteomic biomarkers for gastric adenocarcinoma.

Authors:  Chibo Liu; Chunqin Pan; Yong Liang
Journal:  Exp Ther Med       Date:  2012-03-14       Impact factor: 2.447

5.  Serum amyloid a protein in clinical cancer diagnosis.

Authors:  Chibo Liu
Journal:  Pathol Oncol Res       Date:  2011-09-08       Impact factor: 3.201

Review 6.  Contributions of advanced proteomics technologies to cancer diagnosis.

Authors:  Sergio Ciordia; Vivian de Los Ríos; Juan-Pablo Albar
Journal:  Clin Transl Oncol       Date:  2006-08       Impact factor: 3.405

Review 7.  Moving forward in colorectal cancer research, what proteomics has to tell.

Authors:  Nerea Bitarte; Eva Bandrés; Ruth Zárate; Natalia Ramirez; Jesus Garcia-Foncillas
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

8.  Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis.

Authors:  C Trocmé; H Marotte; A Baillet; B Pallot-Prades; J Garin; L Grange; P Miossec; J Tebib; F Berger; M J Nissen; R Juvin; F Morel; P Gaudin
Journal:  Ann Rheum Dis       Date:  2008-07-29       Impact factor: 19.103

9.  Ovine serum biomarkers of early and late phase scrapie.

Authors:  Isabelle Batxelli-Molina; Nicolas Salvetat; Olivier Andréoletti; Luc Guerrier; Guillaume Vicat; Franck Molina; Chantal Mourton-Gilles
Journal:  BMC Vet Res       Date:  2010-11-02       Impact factor: 2.741

Review 10.  A proteomics view of the molecular mechanisms and biomarkers of glaucomatous neurodegeneration.

Authors:  Gülgün Tezel
Journal:  Prog Retin Eye Res       Date:  2013-02-05       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.